Meeting
2017 ASCO Annual Meeting
Association of the addition of cetuximab to preoperative chemoradiotherapy (CRT) for locally advanced esophageal squamous cell carcinoma (SqCC) with rate of long term survival: Mature results of a prospective phase Ib/II trial.
Authors
Baruch Brenner
Rabin Medical Center, Petah Tikva, Israel
Baruch Brenner , Ofer Purim , Noa Gordon , Tal Goshen Lago , Efraim Idelevich , Hanoch Kashtan , Nikolai Menasherov , Eyal Fenig , Aaron Sulkes , Yulia Kundel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4057)
DOI
10.1200/JCO.2017.35.15_suppl.4057
Abstract #
4057
Poster Bd #
49
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Final analysis of single-arm confirmatory study of diagnostic endoscopic resection(ER) plus selective chemoradiotherapy (CRT) for stage I esophageal squamous cell carcinoma (ESCC): JCOG0508.
First Author: Keiko Minashi
Poster
2011 ASCO Annual Meeting
Concurrent chemoradiotherapy with or without induction chemotherapy for locally advanced head and neck cancer.
First Author: J. J. Caudell
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma: Nationwide real-world data from Japan.
First Author: Jun Okui